| 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 买方营业部 (万元) | | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-15 | 301089 | 拓新药业 | 23.55 | 60.00 | 1,413.00广发证券股份有限 | | 广发证券股份有限 | | | | | | | | 公司佛山顺德大良 | 公司佛山顺德大良 | | | | | | | | 保利国际金融中心 | 保利国际金融中心 | | | | | | | 证券营业部 | | 证券营业部 | 12月15日，拓新药业大宗交易成交60万股，成交额1413万元，占当日总成交额的19.27%，成交价23.55 元，较市场收盘价29.39元折价19.87%。 ...

| | 本报告期 | 本报告期比上年同期 增减 | 年初至报告期末 | 年初至报告期 年同期增 | | --- | --- | --- | --- | --- | | 营业收入(元) | 89.653.837.13 | -16. 21% | 271.553.589.37 | | | 归属于上市公司股东 的净利润(元) | -11.880.527.36 | -1. 258. 62% | -30. 161. 076. 91 | -1, ( | | 归属于上市公司股东 的扣除非经常性损益 的净利润(元) | -13, 735, 220. 65 | -478. 34% | -35.942.839.18 | | | 经营活动产生的现金 流量净额(元) | | | -22,789,583.38 | | 公司2024年实现营业收入4.22亿元，同比下降49.53%；归属于上市公司股东的净利润-1988.49万元，上年同期为2.43亿元；归属于上市公司股东的扣除 非经常性损益的净利润-2725.54万元，上年同期为2.32亿元；经营活动产生的现金流量净额1.03亿元，同比增长280.91%。 中国经济网北京12月14日讯 拓 ...

证券日报网讯 12月11日，拓新药业在互动平台回答投资者提问时表示，截至2025年12月10日，公司股 东户数19015户。 （文章来源：证券日报） ...

证券日报网讯 12月5日，拓新药业（301089）在互动平台回答投资者提问时表示，公司长期致力于医药 健康领域的研发、生产与销售。目前，公司已建立起覆盖原料药、医药中间体及功能食品原料的多元化 业务布局，产品线广泛服务于抗病毒、抗肿瘤、神经系统用药及功能食品等关键健康领域。针对当前国 内流感高发的公共卫生需求，公司全资子公司新乡制药，规模化稳定生产供应利巴韦林原料药。利巴韦 林作为一种广谱强效的抗病毒药物，是相关抗病毒药物的关键成分。公司现有原料药的充足供应，为下 游制剂企业生产流感治疗药物提供了关键保障，有力地支持了市场在流感高发期的用药需求，有助于缓 解相关压力。与此同时，公司正积极布局具有市场前景的抗流感新药研发项目，以应对未来的市场需 求。 ...

格隆汇12月5日丨拓新药业(301089.SZ)在投资者互动平台表示，公司长期致力于医药健康领域的研发、 生产与销售。目前，公司已建立起覆盖原料药、医药中间体及功能食品原料的多元化业务布局，产品线 广泛服务于抗病毒、抗肿瘤、神经系统用药及功能食品等关键健康领域。 针对当前国内流感高发的公 共卫生需求，公司全资子公司新乡制药，规模化稳定生产供应利巴韦林原料药。利巴韦林作为一种广谱 强效的抗病毒药物，是相关抗病毒药物的关键成分。公司现有原料药的充足供应，为下游制剂企业生产 流感治疗药物提供了关键保障，有力地支持了市场在流感高发期的用药需求，有助于缓解相关压力。与 此同时，公司正积极布局具有市场前景的抗流感新药研发项目，以应对未来的市场需求。 ...

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

（文章来源：证券日报） 证券日报网讯 12月3日，拓新药业在互动平台回答投资者提问时表示，截至2025年11月28日，公司股东 户数20014户。 ...

格隆汇12月2日丨拓新药业(301089.SZ)公布，公司子公司拓新药业（内蒙古）有限公司（简称"乙方"） 拟与内蒙古自治区托克托县人民政府（简称"甲方"）签署《内蒙古自治区托克托县拓新药业（内蒙古） 有限公司原料药及健康膳食补充剂生物制造基地建设项目投资协议》。项目名称：原料药及健康膳食补 充剂生物制造基地建设项目。建设规模：项目总投资为4.2亿元，其中固定资产投资3亿元左右。 本次投资项目的建设，能够充分发挥托克托县的地理区位优势与资源禀赋：一方面，为公司打造大规 模、标准化生产基地奠定坚实基础，为研发与生产活动的高效开展创造有利条件；另一方面，当地丰富 的能源资源将直接助力公司降低生产成本，进一步拓宽盈利空间。项目建成投产后，将有效完善公司产 业链布局，巩固市场竞争地位，持续增强公司核心盈利能力与可持续发展能力。 ...

拓新药业（301089）12月2日晚间公告，公司子公司拓新药业(内蒙古)有限公司(以下简称"内蒙古拓新药 业")拟与内蒙古自治区托克托县人民政府签署《内蒙古自治区托克托县拓新药业(内蒙古)有限公司原料 药及健康膳食补充剂生物制造基地建设项目投资协议》。 根据协议，内蒙古拓新药业将在呼和浩特托克托经济开发区建设原料药及健康膳食补充剂生物制造基地 建设项目，该项目总投资为4.2亿元，其中固定资产投资3亿元左右。托克托县人民政府将为内蒙古拓新 药业提供优质服务和良好的发展环境，维护内蒙古拓新药业的正常生产经营秩序；协调兑现本地出台的 招商引资各项优惠和奖励政策。内蒙古拓新药业则必须严格按照协议约定的时限进行开工建设和竣工投 产，并确保协议约定投资额到位。 拓新药业表示，本次投资项目的建设，能够充分发挥托克托县的地理区位优势与资源禀赋：一方面，为 公司打造大规模、标准化生产基地奠定坚实基础，为研发与生产活动的高效开展创造有利条件；另一方 面，当地丰富的能源资源将直接助力公司降低生产成本，进一步拓宽盈利空间。项目建成投产后，将有 效完善公司产业链布局，巩固市场竞争地位，持续增强公司核心盈利能力与可持续发展能力。 拓新药 ...

Core Viewpoint - The company is set to invest 420 million yuan in a new biomanufacturing facility for APIs and health dietary supplements in Inner Mongolia, which will enhance its production capabilities and market position [1] Investment Project Details - The total investment for the project is 420 million yuan, with approximately 300 million yuan allocated for fixed asset investment [1] - The project aims to leverage the geographical advantages and resource endowments of Tokto County, facilitating the establishment of a large-scale, standardized production base [1] Strategic Benefits - The investment will create favorable conditions for efficient R&D and production activities, thereby improving operational efficiency [1] - Abundant local energy resources are expected to help the company reduce production costs and expand profit margins [1] - Upon completion, the project will enhance the company's industrial chain layout, solidify its market competitiveness, and strengthen its core profitability and sustainable development capabilities [1]